Evidence map›Paper›PMID 35760647›Full record

ReviewJournal of autoimmunity2022

The 2022 outbreak and the pathobiology of the monkeypox virus.

Narendra Kumar, Arpan Acharya, Howard E Gendelman, Siddappa N Byrareddy

Open access · greenAbstract readReview
In one paragraph

Review in Journal of autoimmunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed, 5 pooled it
36.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

220 citing papers in PubMed, 5 syntheses or guidelines pooled it, 507 citations in OpenAlex.

  1. Mpox Airborne Transmission: A Systematic Review.Reviews in medical virology · 2026
    Pooled it
  2. Pooled it
  3. Monkeypox-Induced Myocarditis: A Systematic Review.Current problems in cardiology · 2023
    Pooled it
  4. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. First Comprehensive Global Bibliometric Analysis of Monkeypox Virus Research Landscape From 1976 to 2025.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article

160 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Narendra KumarDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Arpan AcharyaDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Siddappa N ByrareddyDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu.
Nebraska Medical Center · USUniversity of Nebraska Medical Center · US

Funding

Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Prodrug Formulations Create Sustained-Release AntiretroviralsR01AI145542 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$5.3M
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9M
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplementR01DA052845 · NIDA · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BYRAREDDY, SIDDAPPA N, MOHAN, MAHESH · 2020 to 2024
$4.0M
Role of HIV Env glycosylation in mucosal transmissionR01AI113883 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N · 2014 to 2018
$3.9M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
LASER ART for PrePR01AI158160 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2021 to 2025
$3.5M
HIV-1DetectionandEliminationFrom CNS Mononuclear PhagocytesR01NS126089 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, GORANTLA, SANTHI · 2021 to 2025
$3.5M
Limiting HIV establishment and maintenace by preserving intestinal immunityR01AI129745 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N, PAIARDINI, MIRKO · 2017 to 2020
$3.3M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
NIAID NIH HHS R01 AI113883NIAID NIH HHS R01 AI129745NIAID NIH HHS R01 AI145542NIAID NIH HHS R01 AI158160NIDA NIH HHS R01 DA052845NIMH NIH HHS R01 MH115860NIMH NIH HHS R01 MH121402NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R01 NS126089NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Following two reports of monkeypox virus infection in individuals who returned from Nigeria to the USA, one who returned to Texas (July 2021) and the other to the Washington, DC area (November 2021), the number of monkeypox infection have dramatically increased. This sounded an alarm of potential for spreading of the virus throughout the USA. During 2022, there was a report of monkeypox virus infection (May 6, 2022) in a British national following a visit to Nigeria who developed readily recognizable signs and symptoms of monkeypox virus infection. Soon following this report, case numbers climbed. By June 10, 2022, more than 1,500 cases were reported in 43 countries, including Europe and North America. While the prevalence of the monkeypox virus is well known in central and western Africa, its presence in the developed world has raised disturbing signs for worldwide spread. While infection was reported during the past half-century, starting in the Democratic Republic of Congo in 1970, in the United States, only sporadic monkeypox cases have been reported. All cases have been linked to international travel or through African animal imports. The monkeypox virus is transmitted through contact with infected skin, body fluids, or respiratory droplets. The virus spreads from oral and nasopharyngeal fluid exchanges or by intradermal injection; then rapidly replicates at the inoculation site with spreads to adjacent lymph nodes. Monkeypox disease begins with constitutional symptoms that include fever, chills, headache, muscle aches, backache, and fatigue. Phylogenetically the virus has two clades. One clade emerged from West Africa and the other in the Congo Basin of Central Africa. During the most recent outbreak, the identity of the reservoir host or the primary carriage remains unknown. African rodents are the suspected intermediate hosts. At the same time, the Centers for Disease Control (CDC) affirmed that there are no specific treatments for the 2022 monkeypox virus infection; existing antivirals shown to be effective against smallpox may slow monkeypox spread. A smallpox vaccine JYNNEOS (Imvamune or Imvanex) may also be used to prevent infection. The World Health Organization (WHO), has warned that the world could be facing a formidable infectious disease challenge in light of the current status of worldwide affairs. These affairs include the SARS-COVID-19 pandemic and the Ukraine-Russia war. In addition, the recent rise in case of numbers worldwide could continue to pose an international threat. With this in mind, strategies to mitigate the spread of monkeypox virus are warranted.

Indexed as

COVID-19Mpox, MonkeypoxAnimalsDisease OutbreaksHumansMonkeypox virusPandemicsAntiviral therapiesMonkeypox outbreak 2022PreventionTransmissionViral pathogenesis

Identifiers

PMID35760647
PMCPMC9534147
OpenAlexW4283445814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.